![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-new20logo-01-1.png\")
<\/p>\n<\/p>\n
![\"Glioblastoma](\"http:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Glioblastoma%20Pipeline%20Insights-01.jpg?1620364568257\")
<\/p>\n
DelveInsight\u2019s<\/span> Glioblastoma Pipeline Insight<\/strong><\/a> report offers a detailed overview of the pipeline therapies that are in various clinical and preclinical stages of growth, as well as their launch and how the market is expected to change as a result across the Glioblastoma domain.<\/span><\/p>\n For Glioblastoma emerging drugs, the Glioblastoma Pipeline Analysis report provides a 360\u00b0 view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA.<\/span><\/p>\n The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.<\/span><\/p>\n Some of the Key Highlights from<\/strong> Glioblastoma Pipeline Report<\/strong><\/a><\/p>\n Request for Sample @<\/span> Glioblastoma Pipeline Insight and Outlook<\/strong><\/a><\/p>\n Glioblastoma: Disease Overview<\/strong><\/a><\/p>\n Glioblastoma, also known as Glioblastoma Multiforme<\/span> is <\/span>a fast growing glioma that develops from star shaped glial cells (astrocytes) that supports the health of nerve cells in the brain<\/span>.<\/strong><\/p>\n Glioblastoma can be located anywhere in the brain and do not regularly spread outside of the brain. Glioblastoma occurs at any age but tends to occur more often in older adults. The World Health Organization classifies glioblastoma into 3 main categories. Glioblastoma isocitrate dehydrogenase (IDH)-mutant, glioblastoma IDH-wild type, and glioblastoma NOS.<\/span><\/p>\n Read more about <\/span>GBM Treatment Market<\/strong><\/a><\/p>\n Glioblastoma <\/span>can occur anywhere in the brain and does not spread outside of the brain on a regular basis. Glioblastoma may strike anyone at any age, but it is more common in older people. Glioblastoma is divided into three groups by the World Health Organization. Isocitrate dehydrogenase (IDH) mutant glioblastoma, IDH wild type glioblastoma, and glioblastoma NOS.<\/span><\/p>\n Glioblastoma: Symptoms<\/strong><\/a><\/p>\n Symptoms include Headaches Seizures, Nausea\/Vomiting, Memory loss and Decrease in normal function.<\/span><\/p>\n \u00a0Glioblastoma: Diagnosis<\/strong><\/a><\/p>\n Individuals suspected of having glioblastoma are subjected to a physical and neurological examination. Brain tumours can be pinpointed with extreme precision using advanced imaging techniques. Computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are two diagnostic instruments (MRI).<\/span><\/p>\n For more information about disease, causes and treatment visit:<\/span> Glioblastoma Pipeline Landscape<\/strong><\/a><\/p>\n Glioblastoma Pipeline Analysis: Drug Profile<\/strong><\/a><\/p>\n ONC201: Oncoceutics<\/strong><\/p>\n ONC201 is the first of a new class of cancer drugs known as imipridones, which work in a different way. The Phase 2 Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma research is currently underway at Oncoceutics. Oncoceutics will enrol patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation in a Phase 2 clinical trial.<\/span><\/p>\n CC 90010 : BMS<\/strong><\/p>\n Celgene, a BMS subsidiary, is developing CC 90010, a reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins. For the treatment of Glioblastoma, the drug is currently in phase I\/II development. Celgene initiated a Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination with Temozolomide With or Without Radiation Therapy in Subjects with Newly Diagnosed Glioblastoma in July 2020 (NCT04324840).<\/span><\/p>\n Gain more knowledge on emerging drugs @<\/span> Glioblastoma Pipeline Therapies<\/strong><\/a><\/p>\n Key Pipeline Therapies and Major Pharmaceutical Companies<\/strong><\/p>\n Glioblastoma Pipeline Therapeutics Assessment<\/strong><\/a> \u00a0<\/strong><\/p>\n Got queries? Reach out for more information @<\/span> Glioblastoma Drug Pipeline Assessment<\/strong><\/a><\/p>\n Scope of the Report<\/strong><\/p>\n Coverage<\/strong>: Global<\/span><\/p>\n Key Players<\/strong>: Tmunity Therapeutics, Myeloid Therapeutics, Oncoceutics, CANbridge Life Sciences, Laminar Pharmaceuticals, BMS, among others.<\/span><\/p>\n Key Pipeline Therapies<\/strong>: Anti-EGFR\/IL-13R alpha 2 CAR T cell therapy, MT201, ONC201, CAN008, Marizomib and 2-OHOA<\/span><\/p>\n Table of Content<\/strong><\/p>\n Know more of what\u2019s covered in the<\/span> Glioblastoma Pipeline Assessment<\/strong> Report<\/strong><\/a><\/p>\n Key Questions Answered in the Glioblastoma Report<\/strong><\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n\n
\n 1.<\/td>\n Introduction<\/span><\/td>\n<\/tr>\n \n 2.<\/td>\n Executive Summary<\/span><\/td>\n<\/tr>\n \n 3.<\/td>\n Glioblastoma: Overview<\/span><\/td>\n<\/tr>\n \n 4.<\/td>\n Glioblastoma- Analytical Perspective In-depth Commercial Assessment<\/span><\/td>\n<\/tr>\n \n 5.<\/td>\n Glioblastoma: Pipeline Therapeutics<\/span><\/td>\n<\/tr>\n \n 6.<\/td>\n Glioblastoma Late Stage Products (Registered)<\/span><\/td>\n<\/tr>\n \n 7.<\/td>\n Glioblastoma Late Stage Products (Phase\u00a0 III)<\/span><\/td>\n<\/tr>\n \n 8.<\/td>\n Glioblastoma Mid Stage Products (Phase\u00a0 II)<\/span><\/td>\n<\/tr>\n \n 9.<\/td>\n Glioblastoma Early Stage Products (Phase\u00a0 II)<\/span><\/td>\n<\/tr>\n \n 10.<\/td>\n Glioblastoma Early Stage Products (Phase I)<\/span><\/td>\n<\/tr>\n \n 11.<\/td>\n Glioblastoma Pre-clinical and Discovery Stage Products<\/span><\/td>\n<\/tr>\n \n 12.<\/td>\n Glioblastoma: Therapeutic Assessment<\/span><\/td>\n<\/tr>\n \n 13.<\/td>\n GlioblMastoma: Inactive Products<\/span><\/td>\n<\/tr>\n \n 14.<\/td>\n Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/td>\n<\/tr>\n \n 15.<\/td>\n Glioblastoma Key Companies<\/span><\/td>\n<\/tr>\n \n 16.<\/td>\n Glioblastoma Key Products<\/span><\/td>\n<\/tr>\n \n 17.<\/td>\n Glioblastoma- Unmet Needs<\/span><\/td>\n<\/tr>\n \n 18.<\/td>\n Glioblastoma- Market Drivers and Barriers<\/span><\/td>\n<\/tr>\n \n 19.<\/td>\n Glioblastoma- Future Perspectives and Conclusion<\/span><\/td>\n<\/tr>\n \n 20.<\/td>\n Glioblastoma Analyst Views<\/span><\/td>\n<\/tr>\n \n 21.<\/td>\n Appendix<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \n